Background

Chronotherapy, which adjusts medication timing to match the human biological clock, has garnered attention as a next-generation therapeutic strategy to maximize drug efficacy and minimize side effects. This is because many human biological indicators, such as liver metabolic enzymes, renal excretion functions, and blood pressure regulating hormones, change regularly according to the 24-hour circadian rhythm. The concept that the same dose of anticancer or cardiovascular drugs could result in significantly different treatment response rates and adverse event frequencies depending on whether they are administered in the morning or evening has raised expectations among clinicians.

However, despite long-standing achievements in basic research, chronotherapy has encountered clear limitations in its process of establishing itself in actual clinical guidelines. This is because the distinct time-dependent effects observed at the cellular or small animal experiment levels have not been consistently reproduced in large-scale Randomized Controlled Trials (RCTs) involving actual patient groups. The structural vulnerability of being difficult to uniformly control with a standardized single timetable—due to individual variations in patients' life cycles, genetic differences, and circadian disruptions caused by disease states—has also hindered commercialization.

Key Findings

Recently, as the field of circadian medicine enters a full-scale clinical phase beyond the laboratory, a situation has occurred where major clinical studies that attracted academic attention have been retracted. A prominent paper that reported demonstrating a reduction in cardiovascular risk based on the timing of drug administration was officially retracted by a journal due to issues with data reliability and flaws in statistical analysis. This was the result of consecutive criticisms from external researchers regarding the randomization procedures in the patient recruitment process, the abnormal uniformity of follow-up data, and the lack of transparency in the statistical analysis process.

This incident directly revealed the vulnerabilities of the chronotherapy field. While reports in basic biological mechanism research have continued to suggest that the therapeutic index of certain anticancer drugs improves by more than twofold according to the expression cycle of clock genes, it has been confirmed that clinical validation yielded exaggerated conclusions without ensuring rigor. It has been pointed out that the lack of electronic monitoring systems to objectively track medication adherence during large-scale clinical data collection, along with a reliance on post-hoc analyses that failed to control for confounding variables, led to research bias.

In light of this retraction, the academic community is revising standard guidelines for chronotherapy research. Rather than focusing on fragmented time differences observed in single-patient cohorts, an alternative has been proposed: the adoption of clinical protocols based on multiple biosignals, integrating continuous blood pressure monitoring devices with wearable activity trackers.

Significance and Outlook

This paper retraction is interpreted not as a setback that shakes the foundation of circadian medicine, but as a self-purifying process leading to the maturity of the field. A consensus has formed that for chronotherapy to move beyond conceptual appeal and establish itself as a pillar of precision medicine, it must move away from empirical medication recommendations and discover personalized circadian biomarkers.

In the future, clinical development is expected to be restructured toward integration with companion diagnostic technologies that measure an individual patient's internal biological clock in real-time. Research is becoming active in identifying the optimal therapeutic window for each patient by analyzing cortisol or melatonin levels in blood or saliva, or gene expression patterns in peripheral mononuclear cells.

However, there are significant barriers to overcome before such precision chronotherapy can be commercialized. A method that adjusts medication timing by measuring each patient's biological rhythm every time would significantly increase the complexity of hospital medication management systems and risk decreasing patient compliance. Regulatory authorities are also demanding much stricter multi-center reproducibility data to approve label expansions that specify medication time windows. The success or failure of chronotherapy's commercialization will depend on how quickly the academic and pharmaceutical industries can restore clinical rigor.